Novel effectors of insulin action in the liver

肝脏中胰岛素作用的新型效应器

• 批准号: 10532746
• 负责人: Fajun James Yang
• 金额: $ 53.34万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-03 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10532746
• 关键词: ADD-1 protein; Acceleration; Acute; Adipose tissue; American; Animal Model; Attenuated; Binding; Biochemical; Cardiovascular Diseases; Chronic; Chronic Disease; Complex; DNA Binding; Data; Development; Diabetes Mellitus; Diabetic mouse; Diagnosis; Diet; Energy Metabolism; Enzymes; Epidemic; Eukaryotic Cell; Exclusion; Fasting; Fatty Liver; GATA4 gene; Gene Delivery; Gene Expression; Genes; Genetic; Genetic Transcription; Genetic Variation; Genetic study; Gluconeogenesis; Goals; Health; Health Care Costs; Hepatic; Hepatocyte; Hormonal; Hormones; Human Genetics; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Resistance; Intervention; Link; Lipids; Liver; MED15; Mammalian Cell; Mediator; Metabolic; Metabolic Diseases; Metabolism; Molecular; Molecular Analysis; Mus; Mutation; Names; Non-Insulin-Dependent Diabetes Mellitus; Nuclear; Nuclear Receptors; Nutritional; Obesity; Obesity Epidemic; Outcome Study; Pathogenesis; Pathology; Phenotype; Phosphoenolpyruvate Carboxylase; Prevalence; Prevention strategy; Preventive; Protein Subunits; RNA Polymerase II; Reagent; Regulation; Reporting; Rodent Model; Role; Signal Transduction; Techniques; Testing; Tissues; Transcriptional Regulation; United States; Work; blood glucose regulation; cofactor; diabetic; endoplasmic reticulum stress; enzyme activity; gain of function; glucose metabolism; glucose production; hepatic gluconeogenesis; human model; insight; insulin regulation; insulin signaling; lipid biosynthesis; lipid metabolism; metabolic abnormality assessment; mouse model; novel; novel therapeutic intervention; overexpression; public health relevance; transcription factor

Project Summary/Abstract: Type 2 diabetes is an epidemic health problem, but in part due to the incomplete understanding on the underlying mechanisms, the current treatments or preventive options are limited. A central paradox in the pathogenesis of type 2 diabetes is the selective mode of hepatic insulin resistance, in which insulin fails to suppress hepatic gluconeogenesis but continues to stimulate lipogenesis, resulting in hyperglycemia and hypertriglyceridemia. Although the acute regulation of glucose and lipid metabolism is largely through changes in metabolite flux and allosteric modulation of key enzyme activities, the chronic regulation of metabolism requires gene transcription. As a cofactor that links multiple transcription factors to RNA polymerase II, the Mediator complex has merged as an important regulator of metabolism. The mammalian Mediator complex is composed of up to 30 subunits. Our central hypothesis is that the Mediator complex integrates hormonal and/or nutritional signals with metabolic gene expression by connecting relevant transcription factors to RNA polymerase II through specific binding domains within particular Mediator subunits. This proposal is focused on a novel interaction between the Mediator subunit MED15 and GATA4 transcription factor. In addition to our previous work showing that MED15 stimulates lipogenesis by co- activating SREBP-1c transcription factor, our preliminary studies support a role of hepatic GATA4/MED15 complex in activating gluconeogenesis and in the development of insulin resistance. Interestingly, although the molecular mechanisms are unknown, human genetic studies indicate that mutations in Gata4 gene (likely gain of function) among all reported genetic variations display the strongest correlation with hypertriglyceridemia. Our hypothesis will be tested in two Specific Aims: Aim 1 will study insulin regulation of hepatic GATA4 in glucose metabolism, and Aim 2 will study the role of hepatic MED15 coactivating SREBP-1c and GATA4 in insulin resistance. A combined genetic and gene delivery approaches together with metabolic, biochemical and molecular analyses will be used to carry out these Aims. All key animal models, reagents and techniques have been established, and supportive preliminary results have been obtained. Overall, successful completion of the proposed studies will yield a novel insight into the mechanisms underlying selective hepatic insulin resistance, and may also aid the development of novel interventional strategies against type 2 diabetes.

项目摘要/摘要： 2型糖尿病是一个流行病问题，但部分原因是对 基本机制，当前的治疗方法或预防选择是有限的。中心悖论 2型糖尿病的发病机理是肝胰岛素抵抗的选择性模式，其中胰岛素无法 抑制肝糖异生，但继续刺激脂肪生成，导致高血糖和 高甘油三酯血症。尽管葡萄糖和脂质代谢的急性调节主要是通过 代谢物通量的变化和关键酶活性的变构调节，慢性调节 代谢需要基因转录。作为将多个转录因子与RNA联系起来的辅因子 聚合酶II（介体综合体）已合并为代谢的重要调节剂。哺乳动物 介体复合物由多达30个亚基组成。我们的中心假设是调解人 复合物将激素和/或营养信号与代谢基因表达相结合 通过特定结合域将相关的转录因子连接到RNA聚合酶II 在特定的调解人亚基中。 该提议的重点是调解器亚基Med15和Gata4之间的新型相互作用 转录因子。除了我们以前的工作表明，Med15刺激了共同发生 激活SREBP-1C转录因子，我们的初步研究支持肝GATA4/MED15的作用 复合激活糖异生和胰岛素抵抗的发展。有趣的是，虽然 分子机制未知，人类遗传研究表明GATA4基因的突变 （可能的功能增益）在所有报道的遗传变异中都显示出与 高甘油三酯血症。我们的假设将以两个具体的目的进行检验：AIM 1将研究胰岛素调节 肝GATA4在葡萄糖代谢中的作用，AIM 2将研究肝Med15共激活的作用 胰岛素抵抗中的SREBP-1C和GATA4。遗传和基因递送的组合方法一起 使用代谢，生化和分子分析将用于执行这些目标。所有关键动物 已经建立了模型，试剂和技术，并且支持性的初步结果是 获得。总体而言，拟议研究的成功完成将产生对 选择性肝胰岛素抵抗的基础机制，也可能有助于新型 针对2型糖尿病的介入策略。